All authors disclose no financial/commercial conflict of interest except that Dr. D. Hoon has licensing agreement with Abraxis Healthcare on several of the biomarkers discussed in this manuscript.
Prognostic molecular biomarkers for cutaneous malignant melanoma†
Article first published online: 9 MAY 2011
Copyright © 2011 Wiley-Liss, Inc.
Journal of Surgical Oncology
Special Issue: Seminars in Surgical Oncology: Melanoma
Volume 104, Issue 4, pages 438–446, 15 September 2011
How to Cite
Tanaka, R., Koyanagi, K., Narita, N., Kuo, C. and Hoon, D. S.B. (2011), Prognostic molecular biomarkers for cutaneous malignant melanoma. J. Surg. Oncol., 104: 438–446. doi: 10.1002/jso.21969
- Issue published online: 17 AUG 2011
- Article first published online: 9 MAY 2011
- Manuscript Accepted: 12 APR 2011
- Manuscript Received: 21 SEP 2010
- Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
- Melanoma Research Alliance
- National Institutes of Health, NCI. Grant Numbers: P0 CA029605, P0 CA012582, R-33 CA100314
- circulating tumor cells;
- lymph node;
Molecular signatures of melanoma have propelled new approaches to early diagnosis, monitoring of treatment response, and targeted therapy. This review discusses messenger RNA (mRNA), genomic, and epigenomic melanoma biomarkers in blood and tissue specimens. The major focus is on tissue-based molecular assays to upstage sentinel lymph nodes (SLNs), and blood-based assays to detect melanoma progression by monitoring levels of circulating tumor cells (CTC) and circulating DNA. J. Surg. Oncol. 2011; 104:438–446. © 2011 Wiley-Liss, Inc.